COMMUNIQUÉS West-GlobeNewswire

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
19/05/2026
Expands intellectual property protection in a strategically important market for the Company’s lead exosome-based therapy targeting nerve repair and functional recovery TORONTO, Ontario and HAIFA, Israel, May 19, 2026 ( [...]
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
19/05/2026
Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to [...]
Ozari Health Launches Nationwide Telehealth Platform for Compounded Semaglutide and Tirzepatide Starting at $86 Per Month
19/05/2026
LegitScript-verified platform connects patients with licensed providers for GLP-1 weight loss treatment, with transparent pricing, multiple pharmacy options, and no long-term contracts. New York, NY, May 19, 2026 (GLOBE [...]
Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur
19/05/2026
Essai de phase IV comparatif direct, en double aveugle, évaluant la tolérance et l’efficacité ayant atteint ses critères principaux et secondaires Les résultats de l’étude DIRECTION montrent que le profil de sécurité de [...]
Olema Oncology to Participate in Upcoming Investor Conferences
19/05/2026
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
19/05/2026
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in [...]
Suja Life to Report First Quarter 2026 Financial Results on June 9, 2026
19/05/2026
OCEANSIDE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life” or the “Company”), a leading better-for-you beverage company and maker of Suja Organic , Vive Organic , and Slice Soda , [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
19/05/2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, [...]
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
19/05/2026
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet [...]
Iridex Reports First Quarter 2026 Financial Results
19/05/2026
2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and [...]
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/05/2026
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and [...]
IBA – ACQUISITION D’ACTIONS PROPRES
19/05/2026
Louvain-la-Neuve, Belgique, 19 mai 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
IBA – ACQUISITION OF OWN SHARES
19/05/2026
Louvain-la-Neuve, Belgium, May 19 th , 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
19/05/2026
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous [...]
Sanofi: Information concerning the total number of voting rights and shares - April 2026
19/05/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
19/05/2026
SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab , the platform-first biotech-startup accelerator founded by Recursion (NASDAQ: RXRX), announced today that its portfolio companies have collectively raised [...]
Radiology Associates of North Texas Announces Analysis Projecting More than $51 Million in No Surprises Act Administrative Costs
19/05/2026
Nation’s largest radiology practice reveals BCBS TX has paid just 2% of binding federal arbitration awards, leaving millions in limbo following recent 5th Circuit ruling Fort Worth, TX, May 19, 2026 (GLOBE NEWSWIRE) -- [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2026
19/05/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
19/05/2026
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin a Phase 2 clinical [...]

Pages